Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Fig. 5

Statistics of engineered NK cell therapies. The pie charts present the types of engineered products under clinical evaluation, as reported on ClinicalTrials.gov until December 2021 (N = 53 trials). For every pie, numbers indicate the percentage of the whole taken by each slice. A Targeting molecules expressed on the surface of engineered NK cells: scFv-engineered chimeric antigen receptor (CAR)-NK, receptor-engineered CAR-NK, CD16-engineered NK and CD16-engineered and scFv-CAR-NK. B Breakdown of the surface tumor antigens targeted by scFv-engineered CAR-NK therapies. C Breakdown of the surface tumor antigens targeted by monoclonal antibodies used in combination with CD16-engineered NK cells. Undisclosed targets are labeled as “Unknown.” In B and C, one trial can have more than one target, belonging to more than one category

Back to article page